ImmunoPhotonics is a technology company.
ImmunoPhotonics has raised $23.6M across 3 funding rounds.
ImmunoPhotonics has raised $23.6M in total across 3 funding rounds.
ImmunoPhotonics has raised $23.6M in total across 3 funding rounds.
ImmunoPhotonics's investors include Andrew Wheeler, iSelect Fund, Mercury Fund, Prelude Ventures, VantagePoint Capital Partners, Cultivation Capital.
# Immunophotonics: Pioneering Interventional Immuno-Oncology
Immunophotonics is a clinical-stage biotech company, not a technology company in the traditional sense—it develops novel cancer therapeutics rather than software or digital platforms.[1][2] The company pioneers Interventional Immuno-Oncology (IIO), a field that combines physical tumor destruction with immune system activation to create systemic, whole-body cancer immunotherapy.[3]
The company's core mission is to transform routine tumor ablation procedures into powerful cancer immunotherapies through its lead asset, IP-001, a proprietary glycan polymer.[4] Immunophotonics serves oncology patients with solid tumors and is exploring applications in infectious disease prevention.[1] The fundamental problem it solves is the limitation of traditional tumor ablation—while ablation destroys local tumors, it typically fails to trigger the immune system to attack distant metastatic cancer. IP-001 addresses this by converting ablated tumor debris into an immune signal that trains the body's killer T cells to seek out and eliminate cancer throughout the body.[4]
The company has demonstrated meaningful growth momentum, raising $21.4 million to advance clinical trials and winning the St. Louis regional finals of the Startup World Cup.[4][7] It is currently in phase 2 development.[2]
Immunophotonics was co-founded by Wei R. Chen, Ph.D., an inventor and researcher specializing in laser medicine and ablation-based immunotherapy.[1] Dr. Chen's research trajectory—spanning decades of work on thermal ablation techniques—culminated in a breakthrough discovery: combining thermal ablation with a novel pharmaceutical agent could achieve systemic antitumor immunity in animals.[1] This foundational research generated numerous patents and publications, including work in the prestigious journal *Science*.[1]
The company is headquartered in St. Louis, Missouri, with a subsidiary in Bern, Switzerland.[1] Lu Alleruzzo, a bioengineer with an MBA, serves as CEO and co-founder and has been instrumental in translating the scientific innovation into a commercial venture.[3] Immunophotonics launched through BioGenerator Labs in the BioSTL Building in St. Louis, positioning itself within a supportive biotech ecosystem.[4]
IP-001 operates through multiple integrated mechanisms that distinguish it from existing immunotherapies:[5]
Rather than requiring entirely new treatment protocols, IP-001 is injected immediately following standard tumor ablation procedures—a significant advantage for clinical adoption.[4] Physicians simply administer the drug at the ablation site, transforming a routine intervention into systemic immunotherapy.[3]
The composition of matter surrounding IP-001 has been patented in over 40 countries representing key oncology markets globally, providing strong intellectual property protection for the platform.[1]
While focused on solid tumors, the company is exploring applications in infectious disease prevention and treatment, suggesting the technology platform has broader therapeutic potential.[1][3]
Immunophotonics operates at the intersection of several converging trends in oncology and immunotherapy. The field of immuno-oncology has matured significantly, with checkpoint inhibitors demonstrating clinical value but facing limitations in patient response rates and durability. Immunophotonics' approach addresses a critical gap: how to generate durable, tumor-specific immune responses in patients who may not respond to existing immunotherapies alone.
The timing is particularly favorable because interventional oncology—minimally invasive tumor ablation techniques—is increasingly standard-of-care for many solid tumors.[4] By leveraging existing clinical infrastructure and procedures, Immunophotonics can potentially achieve faster adoption than therapies requiring entirely new treatment paradigms.
The company also reflects broader recognition that combination approaches drive superior outcomes in cancer treatment. By pairing physical tumor destruction with immune activation, Immunophotonics exemplifies how biotech innovation increasingly focuses on multimodal mechanisms rather than single-target interventions.
Immunophotonics is positioned at an inflection point. The company's phase 2 clinical progress, combined with significant funding and recognition (Startup World Cup win), suggests growing validation of its IIO approach. The critical near-term milestone will be demonstrating clinical efficacy in phase 2 trials—particularly whether IP-001 can generate durable systemic immune responses that translate to improved survival outcomes.
The company's stated need for strategic partnerships indicates awareness that realizing the full potential of its platform will require collaboration with larger pharmaceutical or oncology companies.[3] Such partnerships could accelerate clinical development, expand indications, and bring the therapy to market faster.
Looking forward, Immunophotonics' influence will depend on whether IIO becomes a recognized therapeutic category within oncology. If IP-001 demonstrates compelling clinical benefit, it could reshape how physicians approach solid tumor treatment—converting ablation from a palliative or cytoreductive procedure into a curative immunotherapy. The expansion into infectious disease applications, while speculative, suggests the founders believe the glycan polymer platform has applications far beyond its initial oncology focus.
ImmunoPhotonics has raised $23.6M across 3 funding rounds. Most recently, it raised $21.0M Series B in April 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2022 | $21.0M Series B | Andrew Wheeler, iSelect Fund, Mercury Fund, Prelude Ventures, VantagePoint Capital Partners | |
| Jan 1, 2015 | $600K Series A | Cultivation Capital, Andrew Wheeler, iSelect Fund, Mercury Fund, Prelude Ventures, VantagePoint Capital Partners | |
| Sep 1, 2014 | $2.0M Series A | Cultivation Capital, Andrew Wheeler, iSelect Fund, Mercury Fund, Prelude Ventures, VantagePoint Capital Partners |